- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
San Carlos Today
By the People, for the People
HighVista Strategies LLC Boosts Vaxcyte Stake by 159%
Institutional investor increases holdings in biotech company focused on next-gen preventive vaccines
Mar. 16, 2026 at 11:07am
Got story updates? Submit your updates here. ›
HighVista Strategies LLC, an investment management firm, grew its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 159.4% in the third quarter of 2025. The firm now owns 86,802 shares of the biotech company's stock, valued at $3.1 million. Vaxcyte is a clinical-stage company developing a new generation of preventive vaccines to combat serious bacterial diseases.
Why it matters
Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae. The company's platform aims to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared to conventional approaches. HighVista's increased investment signals confidence in Vaxcyte's technology and pipeline.
The details
According to a 13F filing with the SEC, HighVista Strategies acquired an additional 53,345 shares of Vaxcyte in the third quarter, bringing its total holdings to 86,802 shares. This represents a 159.4% increase in the firm's position. Vaxcyte is focused on developing a new generation of preventive vaccines to combat serious bacterial diseases, with its lead candidate VAX-24 targeting 24 serotypes of pneumococcus.
- HighVista Strategies LLC increased its Vaxcyte holdings in the third quarter of 2025.
The players
HighVista Strategies LLC
An investment management firm that grew its stake in Vaxcyte, Inc. by 159.4% in the third quarter of 2025.
Vaxcyte, Inc.
A clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases.
The takeaway
HighVista Strategies' increased investment in Vaxcyte highlights the potential of the biotech company's innovative vaccine platform, which aims to improve upon conventional conjugate vaccine approaches. As Vaxcyte advances its pipeline, particularly the lead candidate VAX-24, the market will be watching closely to see if the company can deliver on its promise of a new generation of preventive vaccines.
